Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-003 in Healthy Subjects
Latest Information Update: 14 Mar 2025
At a glance
- Drugs HL 003 (Primary)
- Indications Stroke
- Focus Adverse reactions
- Sponsors Kechow Pharma
- 14 Mar 2025 New trial record